Introducing new molecular technologies into routine clinical cancer care: Is there an impact on the treatment of breast cancer?

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Bianchini, G ^a   Gianni, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MICRORNA; NAVELBINE; PACLITAXEL; PLACEBO; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GENETICS; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR GENETICS; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; ARTICLE; BREAST TUMOR; GENETICS; GENOMICS; METHODOLOGY;

BREAST NEOPLASMS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 53449100873     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn446     Document Type: Conference Paper

References (63)

1. Sjöblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
2. Pierga JY, Reis-Filho JS, Cleator SJ et al. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 2007; 96: 341-351.
3. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193.
4. Petros WP, Hopkins PJ, Spruill S et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005; 23: 6117-6125.
5. Schwarzenbach H, Müller V, Beeger C et al. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. Breast Cancer Res 2007; 9: R66.
6. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-298.
7. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction. Nat Rev Cancer 2006; 6: 107-116.
8. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
10. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
11. Kingsmore SF. Multiplexed protein measurement: Technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 2006; 5: 310-320.
12. Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 2006; 5: 1772-1786.
13. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
14. Dupuy A, Simon R. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007; 99: 147-157.
15. Van de Vijver MJ, Yudong HE, Van't Veer L et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
16. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
17. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-7277.
18. Thuerigen O, Schneeweiss A, Toedt A et al. Expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24: 1839-1845.
19. Hess KR, Anderson K, Symmans WF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24: 4236-4244.
20. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
21. Simon R. Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. J Natl Cancer Inst 2006; 98: 1169-1171.
22. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005; 23: 7332-7341.
23. Eifel P, Axelson JA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-989.
24. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANTI for early breast cancer. J Clin Oncol 2005; 23: 2716-2725.
25. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
26. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profi ling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
27. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-92.
28. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
29. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
30. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
31. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expressionbased prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24: 1665-1671.
32. Desmedt C, Piette F, Loi S et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patents in the THANSBIG multicenter independent validation series. Clin Cancer Res 2007; 13: 3207-3214.
33. Habel LA, Shak S, Jacobs KM et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25.
34. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
35. Paik S, Shak S, Tang G et al. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol 2005: 2005 ASCO Annual Meeting Proceedings, (abstract 510).
36. Esteva FJ, Sahin AA, Cristofanilli M et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005; 11: 3315-3319.
37. Albain K, Barlow W, Shak S. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). 30th Annual San Antonio Breast Cancer Symposium, 2007, San Antonio, Texas.
38. Bianchini G, Zambetti M, Mariani P. Recurrence score by OncotypeDX evaluated on the primary breast tumor predicts the 2-year survival after first relapse. 30th Annual San Antonio Breast Cancer Symposium, 2007, San Antonio, Texas.
39. Chang JC, Makris A, Gutierrez MC et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patents. Breast Cancer Res Treat 2008; 108: 233-240.
40. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
41. Goldstein L, Ravdin P, Gray R et al. Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): An analysis of intergroup trial E2197. 30th Annual San Antonio Breast Cancer Symposium, 2007, San Antonio, Texas.
42. Chang HY, Sneddon JB, Alizadeh AA et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
43. Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738-3743.
44. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
45. Loi S, Halbe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through use of genomic grade. J Clin Oncol 2007; 25: 1239-1246.
46. Liu R, Wang X, Chenet GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226,
47. Massagué J. Sorting out breast-cancer gene signatures. N Engl J Med 2007; 356: 294-297.
48. Lusa L, McShane LM, Reid JF at al. Challenges in projecting clustering results across gene expression-profiling datasets. J Nat Cancer Inst 2007; 99: 1715-1723.
49. Kaufmann M, Hortobagyi GN, Goldhirsch S et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006; 24: 1940-1949.
50. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
51. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
52. Chang JC, Wooten EC, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.
53. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004; 64: 8558-8565.
54. Ayers M, Symmans WF, Stec J et al. Gene expression profiles predict complete palthologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22: 2284-2293.
55. Folgueira MA, Carraro DM, Brentani H et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005; 11: 7434-7443.
56. Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in human breast cancer by gone expression profiling. J Clin Oncol 2005; 23: 422-431.
57. Hannemann J, Oosterkamp HM, Bosch CA et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23: 3331-3342.
58. Cleator S, Tsimelzon A, Ashworth A et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006; 95: 229-233.
59. Sørlie T, Perou CM, Fan C et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 2006; 5: 2914-2918.
60. Cleator SJ, Powles TJ, Dexter T et al. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 2006; 8: R32.
61. Harris LN, You F, Schnitt SJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007; 13: 1198-1207.
62. Gong Y, Yan K, Lin F et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: A gene-expression profiling study. Lancet Oncol 2007; 8: 203-211.
63. Symmans WF, Hatzis C, Sotiriou C et al. A genomic index of estrogen receptor reporter genes predicts benefit from adjuvant endocrine therapy independent of baseline prognosis. 29th Annual San Antonio Breast Cancer Symposium, 2006, San Antonio, Texas